Company Filing History:
5 out of 525 
3 out of 3 
3 out of 560 
Years Active: 2013-2019
Title: The Innovative Contributions of Inventor Anne Murray
Introduction
Anne Murray is a renowned inventor based in New York, NY, with a notable portfolio comprising five patents. Her innovative work primarily focuses on the advancements in cancer therapy, particularly through the development of antibodies targeting membrane transporter NaPi2b (SLC34A2).
Latest Patents
Anne’s latest patents highlight her substantial contributions to the field of immunotherapy. Her inventions revolve around the membrane transporter NaPi2b (SLC34A2) as a therapeutic target. One key patent outlines the identification of the SLC34A2 epitope peptide, specifically encompassing amino acids 312-340, which has been recognized as an ovarian cancer epitope through the use of the monoclonal antibody MX35. The use of SLC34A2 and its peptide forms has potential in generating antibodies with anti-tumor properties or in stimulating immune responses. Additionally, the patents cover various types of antibodies, including veneered, chimeric, single chain, and humanized variants. Methods for generating immune responses and treating tumors are also described within her patent applications.
Career Highlights
Throughout her career, Anne Murray has worked with prestigious organizations, including the Ludwig Institute for Cancer Research Limited and the Institute of Molecular Biology and Genetics at the National Academy of Sciences of Ukraine. Her groundbreaking work continues to pave the way for new therapies in cancer treatment.
Collaborations
Murray has collaborated with distinguished colleagues such as Gerd J. Ritter and George Mark, further enhancing her research output and fostering innovation in her field. These collaborations have allowed her to leverage diverse expertise, amplifying the impact of her inventions in cancer therapy.
Conclusion
In conclusion, inventor Anne Murray has made significant strides in the area of cancer therapy through her patented innovations. Her work on antibodies targeting the NaPi2b (SLC34A2) transporter is not only groundbreaking but also essential in the pursuit of effective cancer treatments. As she continues to innovate, the medical community eagerly anticipates her forthcoming contributions to immunotherapy and oncological advancements.